Saturday 17 October 2026
Export COCP’s income statement to Excel — free account
Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
In the quarter to June 2026, revenue fell 81.1%, EPS fell 15.0% and free cash flow fell 16.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.02
0.01
−0.97%
Follow COCP
Cocrystal Pharma, Inc. (COCP) P/E ratio
Cocrystal Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,159× (April 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| Sep 2020 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1,159×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| COCP Cocrystal Pharma, Inc. | n/m |
| ACGN Aceragen, Inc. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| QNTM Quantum Biopharma Ltd. compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| KYNB Kyntra Bio Inc compare | 0.1× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)